. In addition, IL-4 promotes DNA synthesis and short-term proliferation of T-cells (Hu-Li et al., 1987) , thymocytes (Barcena et al., 1991) , fibroblasts (Monroe et al., 1988) and capillary endothelial cells (Toi et al., 1991) . In whole animals the loss of the IL-4 gene (Kühn et al. , 1991; Kopf et al., 1993) or the neutralization ofiL-4 activity (Urban et al., 1991) abolishes the generation oftype 2 helper T -cells (T H2-cells) and the synthesis of IgE. A pathophysiological role of IL-4 is indicated in transgerne mice where the overexpression of IL-4 Ieads to allergic-like inflammatory disease states (Tepper et al., 1990) . Transfeeted tumour cells expressing IL-4 are rejected in vivo by recruited host granulocytes and macrophages (Tepper et al., 1989) . For these reasons IL-4 itself as well as antagonists may be suitable for a number of therapeutic applications.
IL-4 receptors have been identified on a variety of cell types and celllines (for review see Beckmann et al., 1992) .
Typically, IL-4 binding sites occur with a frequency of 300-3000 per cell and exhibit an apparently homogeneous dissociation constant, K 0 , of 50-100 pM. Different cells and cellular responses, however, show large differences in sensitivity to IL-4. Concentrations effecting half-maximal responses (EC 50 values) were reported to range from 0.5 to 200 pM (e.g. Garrone et al., 1991; Rigley et al., 1991; Kruse et al., 1992) . The IL-4 activities are mediated by a receptor system for which up to now only a single protein has been identified. In human cells, this IL-4 binding protein consists of an extracellular domain of 207 amino acid residues, a 24 residue transmembrane segment and an unusually large intracellular domain of 569 amino acid residues (Galizzi et al., 1990; Idzerda et al., 1990) . The extracellular domain alone binds IL-4 with a K 0 of -100 pM. As a member of the haematopoietin receptor family (Bazan, 1990) it is composed of two fibronectin type m modules (Bork and Doolittle, 1992) . In responsive celllines and activated T -cells IL-4 induces a specific pattem of protein tyrosine phosphorylation which differs from that produced by IL-3 (Wang et al., 1992) or IL-2 (lzuhara et al., 1993) .
Deletion analysis indicates that a sequence of amino acids from position 97 to position 137 in the intracellular domain is required for transmission of the growth signal in the Ba/F3 cell line (Harada et al., 1992) .
The three-dimensional structure of human IL-4 has recently been determined in solution (Redfield et al., 1991; Powerset al., 1992; Smith et al., 1992 ; T.Müller, W.Sebald arid H.Oschkinat, submitted) andin crystallized form (Walter et al., 1992a; Wlodawer et al., 1992) . A 4-helix-bundle structure with an up-up-down-down connectivity has been established. A short ß-sheet occurs between two long loops connecting helices A/B and helices C/D. Replacement of cysteines in human IL-4 by threonine residues revealed that the disulfide bridge forrned by cysteines at positions 46 and N.Kruse er al. 99 is essential for the folding of functional IL-4, whereas the other two disulfide bridges formed by cysteines 24/65 and 3/127 are less important (Kruse et al., 1991) . Antagonist or partial agonist variants of human IL-4 were obtained by replacing tyrosine 124 with aspartic acid, glycine, asparagine or Iysine (Kruse et al., 1992) . Receptor-binding residues bad not yet been experimentally identified in human IL-4. Mouse IL-4 variants deficient in receptor binding and/or activation have been reported recently (Morrison and Leder, 1992) . The present results were obtained after a systematic search for functionally important amino acid residues in human IL-4. Remarkably, the mutational analysis produced two types of variants impaired in either receptor binding or receptor activation. The location and functional role of the important amino acid residues identified in human IL-4 suggest similarities with other 'small' cytokines of the 4-helix-bundle protein family, such as granulocyte macrophage colony stimulating factor (GM-CSF) (Diederichs etal., 1991; Walter etal., 1992b) or IL-2 (Bazan, 1992; McKay, 1992; Mott et al., 1992) . Interestingly, in contrast to the human growth hormone (hGH), which represents the prototype of a 'large' 4-he1ix-bundle protein, the antagonismdetermining site of human IL-4 is located on helix D and not, as in hGH, on the site formed by helices A and C (DeVos et al., 1992; Fuh et al. 1992) .
Results

Construction and isolation of /L-4 variants
The IL-4 variants constructed and analysed during the present study are compiled in Tab1e I. The positions to be modified were selected on the basis of the following considerations.
Acidic and basic amino acid side chains are usual1y exposed at the surface of a protein. Consequently, some of the 14 acidic and 27 basic residues present in human IL-4 might be expected to be involved in receptor binding. A subset of 16 of these charged amino acid residues is invariant or highly conserved in the amino acid sequences of the IL-4 from man, mouse, rat, cow and pig (McKnight et al. , 1991; Bailey et al., 1993) . They appear, therefore, tobe of special and general importance despite the species-specificity of IL-4. Only these evolutionarily conserved positions were selected for mutagenesis. The charged residues were replaced by glutamine and in one case by asparagine.
Another set of variants was generated by replacing residues near tyrosine 124 with aspartic acid. In previous experiments replacements of this residue by other amino acid residues and especially by aspartic acid produced partial agonistic or antagonistic variants (Kruse et al. , 1992) . Side chains of residues at positions 120, 121, 123, 125, 127 and 128 would be juxtaposed to tyrosine 124 on the surface of a helix. It was therefore investigated whether an aspartyl residue at these positions might generate partial agonism of the protein.
The variants shown in Table I could be expressed in Escherichia coli in large amounts as inclusion bodies. They were subjected to a renaturation protocol and highly purified by HPLC (see Kruse et al. , 1991) . The final yields were similar (0.5 -2.0 mg per litre of culture) to that obtained with IL-4. Exceptions were variants M120D and C127D which refolded poorly and could be recovered only in low amounts. Variant M120D still contained major contaminants after the final HPLC purification step.
/dentification of /L-4 variants with altered properties during T-ee// proliferation
Most of the IL-4 variants in the first group induced the proliferation of activated T -cells similarly to IL-4 with a halfmaximal response at a concentration of 70-280 pM (see Table 1 ). Four variants, however, clearly exhibited irnpaired activity ( Figure 1A ). lncreased concentrations of variants E9Q and R88Q were necessary to stimulate T -cell proliferation. At sufficiently high doses the maximal response obtained was equal to that produced by IL-4. A more drastic change at these positions in variants E9K and R88D increased the EC 50 > 1000-fold. Nevertheless, at saturating concentrations of variant E9K the maximal IL-4 response was produced. Accordingly, these variants modified at positions 9 or 88 are pure 'EC 50 variants'. Repeatedly, the activity of variant R88D decreased at concentrations above 1 JLM. Therefore, the maximal response could not be established in the T -cell system. Such a decrease in activity was observed also with IL-4 and the other EC 50 variants, although only at concentrations above 10 ~tM (not shown). It has not yet been investigated whether this represents the inhibitory activity of a contaminant or an self-antagonistic activity of the IL-4 proteins. The latter has been observed with hGH (Fuh et al., 1992) . R121D and S125D stimulated T-cell proliferation with EC 50 values of 130 and 140 pM respectively, similar to that of IL-4; the maximal response, Rmax, however, was only 30% of the maximal IL-4 response. These variants are therefore defective in receptor activation. In this respect R121D and Sl25D resemble variants Y124G, Y124N and Y124K which have been studied previously (Kruse et al., 1992) . The Rmax variants R121D and S125D arealso partial
antagonists. IL-4-stimulated T -cell proliferation could be inhibited by these variants down to a value corresponding to their maximal partial agonist activities. The competitive inhibitor constants, Ki, were 300-600 pM, not much higher than the EC 50 values of their partial agonist activities (data not shown). These results support the conclusion that these variants have a reduced signaHing activity. Remarkably, the drastic Substitutions generated in variants Kl23D and Sl28D did not measurably change the functional properties of these proteins under our experimental conditions. The variant C127D exhibited a modest increase in the EC 50 value. The significance of this remains unclear.
The same applies for the slightly reduced Rmax value and the 100-fold increased EC 50 value of variant M120D. Considering the poor yields after renaturation and purification, structural instability and major folding defects appear to be possible for C127D and especially for the Ml20D variant (see Discussion). Figure 2B ) and Yl24D (Kruse et al., 1992) bind to the IL-4 receptor of Raji cells with a K 0 comparable to that of normal IL-4. The inefficient receptor activation is not reflected by an altered apparent K 0 . While it is unknown whether Raji cells express a functional IL-4 receptor, previous experiments employing primary human T -cells and B-cells have also established that the highly deficient Rmax variant Yl24D binds to the receptor of these cells with a K 0 of -300 pM. This value is 3-fold larger than the K 0 of IL-4, 100 pM (Kruse et al., 1992) , which has been determined not only in primary cells but also in a variety of IL-4-responsive cell lines (see Beckmann et al., 1992) .
Receptor binding of /L-4 vsrisnts studied with the receptor of Rsji cells
Dose-response measurements of EC 50 variants during a highly sensitive 8-ce/1 assay
Human IL-4 induces the expression of CD23 (Fcdl) in purified B-cells at EC 50 values of 2-10 pM (Kruse et al. , 1992) . This B-eeil response is -50 times more sensitive than the proliferative response of T-cells (see above different receptor system exists in B-cells; this is supported by the observation that IL-4-induced expression of CD23 on human B-cells is regulated independently from that of IgM (Rigley et al. , 1991) . It was therefore interesting to examine how far the EC 50 variants show a similar increase in EC 50 during the B-eeil assay and during the T -cell response described above. The experiment presented in Figure 3 yielded EC 50 values of 2. 7 pM for the IL-4-dependent induction of the mean CD23 content, and 0.3 pM for the induction of the percentage of CD23 positive cells, in accordance with previously described experiments (Kruse et al., 1992) . The variants E9Q and R88Q produced a half-maximal response only at 30-50 times higher concentrations (see also for half-maximal CD23 induction were 2000-10 000 times higher than those required for IL-4. As statistically evaluated and compiled in Table II , these relative EC 50 values are remarkably similar to those observed during the T -cell assay, despite the fact that the absolute EC 50 values for the responses of the two cellular systems differ by about two orders of magnitude. These observations give further support to the view that the sarne IL-4 receptor system operates in B-and T -cells at least as far as the Iigand binding and receptor activation is concemed.
Receptor binding of /L-4 variants as studied with the isolated extracellular domain of the /L-4 receptor
The extracellular domain of the human IL-4 receptor (IL-4ReJ comprising amino acid residues 1-207 of the mature receptor proteinwas expressed in CHO cells and highly purified by affinity chromatography on IL-4-Sepharose. A solid-phase assay employing streptavidincoated wells of a microtitre plate and immobilized biotinylated IL-4Rex was developed in order to analyse the binding properties of IL-4 variants. Such a system is more convenient to handle than whole cells. Furthermore, the properties of immobilized IL-4Rex can be compared with those of the functional receptor. Analysis of purified IL-4Rex using chemical crosslinking and gel chromatography revealed no oligomeric forms of the protein (S.Amold and W.Sebald, unpublished observation). Thus, IL-4Rex becomes immobilized probably as a monomer, and a 1 : 1 interaction of IL-4 protein and the receptor can be Figure 4 . Half-maximal binding is observed at 100 pM IL-4. Nonspecific binding determined in the presence of 500 nM unlabelled IL-4 is < 10%. The K 0 value observed with immobilized IL-4Rex is remarkably similar to the K 0 values of 50-100 pM found for the binding of IL-4 to whole Raji cells, B-cells or T -cells at 4 °C (e.g. Kruse et al., 1992) .
Competitive radioligand binding experiments revealed ( Figure 5A ) that relative to IL-4 the EC 50 variants E9Q and R88Q bound to IL-4Rex with a 410-fold and 1400-fold increased K 0 respectively. The relative K 0 s of E9K and R88D were slightly higher. These results clearly indicate that a defective interaction with the extracellular domain of the known IL-4 receptor protein causes the increased EC 50 values of this group of variants.
The binding properties of Rmax variants R121D, Sl25D and Y124D ( Figure SB) clearly differ from those of the EC 50 variants described above. They bind to immobilized IL-4Rex with a K 0 similar to. that of normal IL-4. Remarkably, the inefficient receptor activation is not reflected by an altered interaction between this type of IL-4 variant and the isolated receptor protein.
A quantitative evaluation and a comparison of the altered responses of EC 50 variants (and Rmax variants) are presented in 
Two functional sites of human IL-4
Zurawski and Zurawski, 1989) . Considering the different experimental set-ups during competitive radioligand binding and during the biological response measurements, a more complex effect of amino acid substitutions during the cell culture experiments appears to be possible. For example, the IL-4 system in B-and T -cells is probably not in thermodynamic equilibrium, since the receptor off-rates are lower than the intemalization rates for the Iigand-receptor complex (Galizzi et al., 1989; Liang et al., 1992) .
Consequently, the biological responses are largely determined by the receptor on-rate. It can be visualized that the on-and off-rates are altered to a different extent in the E9Q and R88Q variants.
Discussion
The (0) and S125D (.6).
Fig. 6. Schematic drawings of the three-dimensional structure of human IL-4 showing views of helices A and C (left) and helices D and A (right).
Closed circles indicate the approximate locations of 'binding residues' glutamic acid 9 (E9) and arginine 88 {R88) as weil as of 'signalling residues' acid arginine 121 {Ri21), tyrosine 124 (Y124) and serine 125 (S125). (Arginine 88 is located at the back of the protein in the D-A view.) Open circles designate the other positions which so far have been altered by amino acid subsitutions [see TableI and Kruse et al., (1991).] marked by glutamic acid 9 in helix A and arginine 88 in helix C. The location of these residues is depicted in the two schematical views of human IL-4 in Figure 6 . The established three-dimensional structure of human IL-4 shows that these amino acid side chains are exposed completely or, in the case of tyrosine 124, partially at the surface of the protein (e.g. T.Müller, W.Sebald and H.Oschkinat, submitted). Furthermore, the 'binding residues' at positions 9 and 88 are juxtaposed, as are the 'signalling residues' at positions 121, 124 and 125. The functional sites marked by the mutational analysis are therefore compatible with the topology and location of the involved residues. Amino acid Substitutions at other positions which have been analysed in the present and a previous study (Kruse et al. , 1992) did not produce major functional alterations. A few substitutions interfered with the folding and/or stability of the protein.
These negative results do not exclude the possibility that residues at these positions are of functional importance. The replacements performed up to now with only one single amino acid residue may be too insignificant to cause measurable functional defects. Severallines of evidence support the view that the amino acid substitutions causing the functionally deficient IL-4 variants discussed above do not produce major alterations in the protein fold. (i) The Rmax variants bind with largely unchanged affmity for IL-4Rex· Thus, the alterations in helix D apparently remain essentially confined to the 'signalling site', and they leave the 'binding site' intact (see also T.Müller, W.Sebald and H.Oschkinat, submitted). (ii) 
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The EC 50 variants as weil as the Rom variants are renatured and purified from inclusion bodies in yields similar to When reanalysed by HPLC, the protein is eluted as a symmetrical peak at the IL-4 retention time. (iv) Furthermore, certain monoclonal antibodies against human IL-4, which are sensitive to structural perturbations, bind with normal affinity to these variants (Reusch et al. , unpublished Observations) .
Our conclusions are at variance with some of the interpretations deduced from the study of mouse IL-4 mutant proteins (Morrison and Leder, 1992) . Mouse IL-4 variants were generated by alanine-scanning mutagenesis and expressed in CHO cells as fusion proteins with alkaline phosphatase. The mousevariant El2A modified at glutamic acid 12 (which corresponds to human IL-4 glutamic acid 9) exhibited a > 100-fold reduced bioactivity and receptor binding affmity. lt was suggested that this residue is important for structural integrity. A series of mouse IL-4 variants with modifications in helix D (L104A, Dl06A, F107 A and L111A) each lost both binding and biological function. It was suggested that helix D was part of the receptor binding domain of mouse IL-4 and, more specifically, it was proposed that the side chains of leueine 104, aspartic acid 106, phenylalanine 107 and leueine 111 contributed most to the binding interactions in this region. Perhaps some of these interpretations were premature. It is reasonable to assume that the three-dimensional structures of mouse and human IL-4 are largely comparable, despite species-specificity in receptor binding and bioactivity.
According to the now available structural data on human IL-4, the side chains of the invariant leueine 104, phenylalanine 107 and leueine 111 areintegral constitutents of the hydrophobic core and consequently would not be available for receptor interactions. On the other band, despite the determinants for species-specificity in the first 16 amino acid residues of mouse IL-4, it is quite possible that the invariant side chain of glutamic acid 12 functions in receptor bindingalso in mouse IL-4. Adefinite decision, however, requires a structural analysis of these mutant proteins. Interestingly, a deletion of the last C-terminal amino acids of mouse IL-4 generates a variant highly deficient in bioactivity but retaining normal receptor-binding affmity. The deleted residues can be aligned to Iysine 123 and also tyrosine 124 and serine 125 of human IL-4 functioning in receptor activation. Thus, a 'signalling site' appears tobe present also at the corresponding positions in the helix D of mouse IL-4.
Human GM-CSF and human IL-2 are folded remarkably similarly to human IL-4 despite the fact that the amino acid sequences are only vaguely related. All three proteins consist of -130 amino acid residues. The 4-helix-bundle structures show the same up-up-down-down connectivity ('doubleoverhand' topology), and the long AB and CD loops are connected by a short ß-sheet. Parts of their three-dimensional structures are nearly superimposable (Wlodawer et a/., 1992;  T.Müller, W.Sebald and H.Oschkinat, submitted). Some variability exists in the length of the N -terminal end of helix C which is shorter in GM-CSF, and which appears tobe shortened also in equine, porcine and mouse IL-4 (Bailey et a/., 1993; E.V.Vandergrifft and D.H.Morokov, EMBL database accession no. L06010). A specific feature of the GM-CSF and IL-2 structures is a short helical segment after helix A on the head of the helix bundle, which is not seen in human IL-4. It is also interesting to note that the dimeric human M-CSF, which represents another 4-helix-bundle protein, is connected via the heads of the two protein molecules (Pandit et al. 1992) .
Mutational analysis of human IL-2 revealed that aspartic acid 20 functions in IL-2 binding to the medium-and highaffmity receptor (Weigel et al., 1989; Sauve et a/., 1991) , probably by interacting with the ß subunit of the IL-2 receptor (IL-2Rß). Similar results have been reported for variants of mouse IL-2 with substitutions of aspartic acid 34 (Zurawski et al., 1990) , which corresponds to human IL-2 aspartic acid 20. In human GM-CSF, glutamic acid 21 determines high-affmity binding to the GM-CSF receptor (Lopez et al., 1992; Shanafelt and Kastelein, 1992) . Because low-affinity binding to the GM-CSF receptor a subunit is not affected in glutamic acid 21 variants, it was reasonable to conclude that this residue interacts directly with the GM-CSF receptor ß subunit (GM-CSFR,ß). Glutamic acid 9 of human IL-4, which has been shown to determine binding to IL-4Rex in the present study, is 1ocated at the equivalent position to GM-CSF glutamic acid 21 or human IL-2 aspartic acid 20 (Wlodawer et al., 1992) . On the basis of superficial similarities between the amino acid sequences the functional equivalence of each of these positions has been postulated before (Shanafelt et al., 1991) . The present findings support the view that an acidic side chain in helix A functions at least in the 'small' helical cytokines in binding to a receptor subunit.
Helix C of IL-2 or GM-CSF has not been studied at the Two functional sites of human IL-4
Ievel of single amino acid replacements. Kaushansky (1992) identified the sequence between residues 78 and 87 in helix C of human GM-CSF as the receptor recognition region. Glutamine 86 is located near glutamic acid 21 in the threedimensional structure of GM -CSF, like the side chains of arginine 88 and glutamic acid 9 in human IL-4. Thus, a 'binding site' including amino acid side chains from helices A and C may be common to these cytokines. lt is tempting to speculate that the receptor subunit binding to this site also exerts a common function in the various receptor systems. This may hold true especially for the extracellular domain which binds the Iigand. The fmding that chimeric receptors constructed from the intra-and extracellular domains of the IL-3Rß and IL-2Rß subunits induce a tyrosine phosphorylation pattem determined by the extracellular Iigand-binding domain (Chiba et a/., 1993) supports this assumption. A common functional role would imp1y that the extracellular domain of the IL-4 receptor (IL-4ReJ is equivalent to the complex ofthat of GM-CSFRa and GM-CSFRß and that of IL-2Ra and IL-2R,ß. Theseparated ß subunits of these two receptor systems per se have no or only very low binding affinity for the ligands. The IL-2Ra subunit binds to amino acid residues (arginine 38 and phenylalanine 42) in the small helix at the head of human IL-2 (Weigel et al., 1989; Sauve et al., 1991) . It has been postulated that the GM-CSFRa subunit binds to helix D of GM-CSF (Kastelein and Shanafelt, 1993) but no experimental data that confirm this conclusion have been presented. If the functional and structural equivalence ofthe system holds true, GM-CSFRa should bind to the head of GM-CSF. The receptor subunit binding to the side chains at positions 121, 124 and 125 in helix D of human IL-4 remains still undefmed. In principle, it could be a second molecule of IL-4Rex or even a second contact site within IL-4Rex after an allosteric conformational change. Up to now it has not· been possible to establish IL-4-dependent dimerization of the IL-4 receptor or of IL-4Rex (S. Amold et al., unpublished observation) . No second binding site to IL-4Rex was detected in the EC 50 variants described in the present experiments. Thus, the association with a second, hitherto unknown IL-4 receptor subunit appears to be possible. It is conceivable that the formation of such a heterodimer ( or a higher aggregate of the dimer) represents the signalling event which triggers the aggregation of the intracellular cytosolic domains (Ullrich and Schlesinger, 1990) . Such a situation would correspond to a model of the IL-2 system which has recently been formulated (for review see Voss et al., 1993) . An IL-2R-y subunit has been identified which appears to interact directly with IL-2 after a contact with the complex of the ß plus ' Y subunits ( or a plus ß plus ' Y subunits) has been established. This interaction with the ' Y subunit probably involves glutamine 141 in helix D ofmouse IL-2. Variants affected at this positionexhibitpartial agonist activity (lmler and Zurawski, 1992) . They are similar in this respect to the Rmax variants of human IL-4.
The results obtained with human IL-4 correspond to findings with hGH as far as the existence of two functionally distinct sites for receptor (hGH-BP) interactions are concemed. Surprisingly, however, they differ with respect to the functional role ofthese sites. Growth hormone binds two molecules of hGH-BP in an ob Iigatory, sequential twostep mechanism (Cunningham et al., 1991) . The first hGH-BP binds to site 1 of hGH provided mainly by residues on helix D, and by residues on one side of helix A and in the loop region between helices A and B. This first interaction of hGH with hGH-BP has a K 0 of -200 pM. The 1: 1 complex between hGH site 1 and hGH-BP then binds in a subsequent step a second hGH-BP molecule via site 2. Site 2 comprises residues on helices A and C (De Vos et al. , 1992) and from the loop between helices B and C. lt is the 'signalling site' and determines the efficacy and agonist activity of hGH. Accordingly, an antagonistic hGH variant (G120R) could be constructed by abolishing binding to site 2 (Fuh et al., 1992) . This bloclcs the receptor activation process at the Ievel of the inactive 1: 1 complex. Similarly, the receptor system was shifted to the inactive 1: 1 complex by a large excess ( > 1 pM) of hGH. In human IL-4 the location ofthe 'binding site' and the 'signalling site' appears tobe reversed. If a sequential binding mechanism exists also in the human IL-4 receptor systems then the frrst step would be an interaction via helices A and C of IL-4 and the subsequent step would be an interaction via helix D. Such a mechanism would, of course, have irnportant irnplications for the rational design of high affinity IL-4 antagonists.
Materials and methods
Mutsgenesis and Isolation of /L-4 variants
Mutagenesis of the ll.A cONA was performed either according to the gapped duplex method (e.g. K.ruse et al., 1991) or by means of recombinant polymerase chain reaction employing two primers complementary for parts oftheir 5' and 3' ends (Higuchi, 1990) . The manipulated IL-4 cONA was expressed in E. coli and the IL-4 variant protein was renatured and highly purified as described by K.ruse et al. (1992) . Protein concentration was determined by measuring absorbance at 280 nm.
Ouring some experiments, variants E9Q, E9K, R88Q and R880 were concentrated to 400 1-'M (6 mg protein/ml) by the following protocol. After HPLC, the proteinwas frozen in an alurninium block at -70°C and freezedried under high vacuum ovemight. About 1 mg of the dry, cotton-like proteinwas dissolved in 0.1 ml water. The pH was adjusted to 8 by addition of20 1-' 1 of 1M Tris-acetate, pH 8. The solutionwas dialysed extensively against 20 mM Tris-HCI, 1 mM EOTA, pH 8. Protein was diluted to 6 mglml with the same buffer. The solution was frozen in aliquots at -20°C.
Biological assays
ONA synthesis in peripheral blood cells [largely T -cells (PHA blasts)] was determined in duplicate by incorporation of [3H]thymidine. EC 50 values were calculated from the data obtained in at least three different experiments. The EC 50 values were distributed log normal. Standard deviations (SO) were calculated from log EC 50 ± log SO. SO was 1.9-fold for different preparations of IL-4, and 2.3-fold of the mean EC 50 for all variants except E9Q, E9K, R88Q, R880, M1200 and C127D. The SD of the Rmax values for IL-4 was ±9; that for all variants except R121D and S1250 was ± 13. Induction of C023 in purified B-cells was analysed by fluorescence-activated cell sorting (FACScan, Becton-Oickinson) (K.ruse et al., 1992) .
Competitive radio/igand binding
Iodination of recombinant human IL-4 and binding experiments employing Raji cells were performed at least three times in duplicate as described elsewhere (K.ruse et al., 1992) . The relative IC 50 values were distributed log normal. Standard deviations (SO) were calculated from log IC 50 ± log SO. SO was 1.3-fold for measurements with IL-4, and 2-fold of the mean IC 50 for all variants except E9Q, E9K, R88Q, R880, M1200 and C1270.
The recombinant extracellular domain of the IL-4 receptor (IL-4Rex> was isolated from the supematants of a CHO cell line stably transfected with cONA encoding residues -25 to 207 ofthe human IL-4 receptor (S.Amold and W.Sebald, unpublished; e.g. Mosley et al., 1989) . The IL-4Rex was highly purified by affmity adsorbtion to an IL-4-Sepharose 4B matrix and by subsequent chromatography on Superose 12 (Pharmacia). The purified IL-4Rex was reacted with a 5-fold molar excess of sulfo-NHS-LC-biotin (Pierce), and the mixturewas desalted by a passage over BioGel P6 (BioRad). The biotinylated IL-4Rex was immobilized on streptavidin-coated 
